Atlas Trials

Study to Evaluate Safety & Tolerability of AGI-134 in Solid Tumour

Clinical trial NCT03593226 · COMPLETED

Trial details

NCT number
NCT03593226
Sponsor
Agalimmune Ltd.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Superficial, Palpable, Unresectable/Metastatic Solid Tumour
Start date
2018-11-30
Primary completion
2023-12-31
Enrollment
38

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.